经过长达5年的法律斗争，GSK最终还是选择了和解。10月9日，GSK宣布就其胃灼热药物Zantac致癌问题诉讼案与10家原告公司达成和解，GSK需要为大约80000起诉讼支付22亿美元，为每位索赔人支付大约27500美元，避免其在美国面临的93%州诉讼案。同时，对首个发出Zantac致癌风险警告的美国独立实验室Valisure，GSK也同意了以7000万 ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

近日，辉瑞宣布终止针对呼吸道合胞病毒（RSV）治疗药物sisunatovir的开发。根据10月7日ClinicalTrials.gov网站的更新，辉瑞已经停止了两项关于sisunatovir治疗RSV感染的临床研究。

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

2024年9月19日，这场纠纷有了新进展，美国加利福尼亚中区联邦地区法院的陪审团一致裁定Axonics未侵犯美敦力所主张的三项专利权。Axonics对此结果表示满意，并将继续致力于改善患有膀胱和肠道功能障碍成年人的生活质量。

智通财经APP获悉，葛兰素史克(GSK.US)用于治疗一种常见鼻炎的实验性药物在两项后期试验中显示出积极的结果，这促进了这家英国制药商的研发管道。据了解，Depemokimab有助于减少患有慢性鼻窦炎伴鼻息肉患者的鼻塞和息肉大小，葛兰素史克表示，这是 ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

领先的制药公司GSK plc (NYSE:GSK)今天宣布达成和解,以解决美国州法院大多数未决的Zantac(雷尼替丁)产品责任案件。该公司将支付高达22亿美元来解决约8万起案件,占针对该公司索赔的93%。此外,GSK原则上同意以7000万美元和解Valisure提起的qui tam诉讼。 这些和解并不意味着GSK承认任何责任,预计将在2025年上半年末前全面实施。GSK坚持认为,没有确凿的科学证 ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old ...

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...